$CRNX
Crinetics Pharmaceuticals, Inc. Stock $crnx

$crnx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024022108 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$640.0K	$0.00	$4.013M
YoY Change	-76.11%	-100.0%	-15.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$20.83M	$17.08M	$58.09M
YoY Change	70.88%	51.48%	37.03%
% of Gross Profit
Research & Development	$53.34M	$45.58M	$168.5M
YoY Change	38.66%	23.22%	29.41%
% of Gross Profit
Depreciation & Amortization	$474.0K	$262.0K	$1.100M
YoY Change	67.49%	-6.43%	10.0%
% of Gross Profit
Operating Expenses	$74.17M	$62.66M	$226.6M
YoY Change	46.41%	29.82%	31.28%
Operating Profit	-$73.53M		-$222.6M
YoY Change	53.26%		32.6%
Interest Expense	$7.320M	$29.82M	$36.44M
YoY Change	269.14%	-2.45%	10.69%
% of Operating Profit
Other Income/Expense, Net	$7.069M	-$23.06M	$13.28M
YoY Change	256.48%	-17.66%	166.93%
Pretax Income	-$66.46M	-$55.90M	-$214.5M
YoY Change	44.49%	24.24%	30.88%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$66.93M	-$60.10M	-$214.5M
YoY Change	45.52%	33.58%	30.88%
Net Earnings / Revenue	-10457.81%		-5345.85%
Basic Earnings Per Share	-$0.93		-$3.69
Diluted Earnings Per Share	-$0.93	-$0.89	-$3.69
COMMON SHARES
Basic Shares Outstanding	69.60M	66.80M	58.07M
Diluted Shares Outstanding	72.29M		58.07M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$601.2M	$129.0M	$558.6M
YoY Change	140.23%	-58.57%	67.02%
Cash & Equivalents	$395.9M	$54.90M	$54.90M
Short-Term Investments	$205.2M	$74.09M	$503.7M
Other Short-Term Assets	$3.556M	$1.578M	$6.500M
YoY Change	8.18%	-37.75%	-23.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$114.0K	$90.00K
Total Short-Term Assets	$917.2M	$574.2M	$574.2M
YoY Change	200.33%	66.33%	66.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.87M	$10.88M	$57.43M
YoY Change	263.29%	210.89%	1051.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$470.0K	$470.0K
YoY Change
Other Assets	$2.000M	$2.000M	$3.300M
YoY Change	0.0%	5305.41%	64.51%
Total Long-Term Assets	$60.93M	$61.20M	$61.20M
YoY Change	607.94%	775.29%	775.29%
TOTAL ASSETS
Total Short-Term Assets	$917.2M	$574.2M	$574.2M
Total Long-Term Assets	$60.93M	$61.20M	$61.20M
Total Assets	$978.2M	$635.4M	$635.4M
YoY Change	211.5%	80.41%	80.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.76M	$6.548M	$6.548M
YoY Change	82.46%	-4.87%	-4.87%
Accrued Expenses	$38.55M	$35.34M	$35.34M
YoY Change	110.59%	89.99%	89.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$51.77M	$43.94M	$43.94M
YoY Change	96.68%	58.5%	58.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$51.45M	$52.31M	$52.31M
YoY Change	599.28%	543.75%	543.75%
Total Long-Term Liabilities	$51.45M	$52.31M	$52.31M
YoY Change	599.28%	543.75%	543.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.77M	$43.94M	$43.94M
Total Long-Term Liabilities	$51.45M	$52.31M	$52.31M
Total Liabilities	$103.2M	$96.25M	$96.25M
YoY Change	206.48%	168.49%	168.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$720.6M	-$653.7M
YoY Change	48.52%	48.84%
Common Stock	$881.0K	$253.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$874.9M	$539.1M	$539.1M
YoY Change
Total Liabilities & Shareholders Equity	$978.2M	$635.4M	$635.4M
YoY Change	211.5%	80.41%	80.41%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$66.93M	-$60.10M	-$214.5M
YoY Change	45.52%	33.58%	30.88%
Depreciation, Depletion And Amortization	$474.0K	$262.0K	$1.100M
YoY Change	67.49%	-6.43%	10.0%
Cash From Operating Activities	-$52.86M	-$38.52M	-$166.3M
YoY Change	29.81%	9.4%	44.36%
INVESTING ACTIVITIES
Capital Expenditures	$1.332M	$935.0K	$4.688M
YoY Change	8225.0%	241.24%	183.09%
Acquisitions
YoY Change
Other Investing Activities	$1.641M	-$86.37M	-$195.7M
YoY Change	-96.64%	-332.64%	13.58%
Cash From Investing Activities	$309.0K	-$87.31M	-$200.4M
YoY Change	-99.37%	-336.91%	15.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$350.0M		$369.0M
YoY Change			214.75%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	393.6M	37.93M	388.9M
YoY Change	81216.94%	32878.26%	218.9%
NET CHANGE
Cash From Operating Activities	-52.86M	-38.52M	-166.3M
Cash From Investing Activities	309.0K	-87.31M	-200.4M
Cash From Financing Activities	393.6M	37.93M	388.9M
Net Change In Cash	341.0M	-87.90M	22.22M
YoY Change	3902.19%	-5091.37%	-113.29%
FREE CASH FLOW
Cash From Operating Activities	-$52.86M	-$38.52M	-$166.3M
Capital Expenditures	$1.332M	$935.0K	$4.688M
Free Cash Flow	-$54.19M	-$39.45M	-$171.0M
YoY Change	33.03%	11.19%	46.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001658247
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38583
CY2023	dei	Entity Registrant Name EntityRegistrantName	Crinetics Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3744114
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	6055 Lusk Boulevard
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	450-6464
CY2022Q4	crnx	Investment In Radionetics InvestmentInRadionetics	0
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1300000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1301000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2000000
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	CRNX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1000000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69596202
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	San Diego
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54897000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32672000
CY2023Q4	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	502681000
CY2022Q4	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	305684000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	503658000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	301753000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15598000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10759000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	574153000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	345184000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10881000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3500000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46549000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1486000
CY2023Q4	us-gaap	Derivative Assets DerivativeAssets	0
CY2022Q4	us-gaap	Derivative Assets DerivativeAssets	668000
CY2023Q4	crnx	Investment In Radionetics InvestmentInRadionetics	470000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37000
CY2023Q4	us-gaap	Assets Assets	635353000
CY2022Q4	us-gaap	Assets Assets	352176000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23196000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	15351000
CY2023Q4	crnx	Accrued Compensation And Related Expense AccruedCompensationAndRelatedExpense	14517000
CY2022Q4	crnx	Accrued Compensation And Related Expense AccruedCompensationAndRelatedExpense	9081000
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	2056000
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	2240000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4173000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1051000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	43942000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27723000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47555000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2024000
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4750000
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6101000
CY2023Q4	us-gaap	Liabilities Liabilities	96247000
CY2022Q4	us-gaap	Liabilities Liabilities	35848000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68175000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68175000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53877000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53877000
CY2023Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1191831000
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	759432000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	977000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3931000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-653702000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-439173000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	539106000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316328000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	635353000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	352176000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4013000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4737000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1078000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	168527000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	130225000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	84255000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	58094000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42394000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24525000
CY2023	us-gaap	Operating Expenses OperatingExpenses	226621000
CY2022	us-gaap	Operating Expenses OperatingExpenses	172619000
CY2021	us-gaap	Operating Expenses OperatingExpenses	108780000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-222608000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-167882000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-107702000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	13436000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4317000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	157000
CY2023	crnx	Change In Valuation Of Derivative Assets ChangeInValuationOfDerivativeAssets	0
CY2022	crnx	Change In Valuation Of Derivative Assets ChangeInValuationOfDerivativeAssets	600000
CY2021	crnx	Change In Valuation Of Derivative Assets ChangeInValuationOfDerivativeAssets	0
CY2023	crnx	Other Income Expense OtherIncomeExpense	-159000
CY2022	crnx	Other Income Expense OtherIncomeExpense	57000
CY2021	crnx	Other Income Expense OtherIncomeExpense	-96000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13277000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4974000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	61000
CY2023	crnx	Loss Before Equity Method Investment LossBeforeEquityMethodInvestment	-209331000
CY2022	crnx	Loss Before Equity Method Investment LossBeforeEquityMethodInvestment	-162908000
CY2021	crnx	Loss Before Equity Method Investment LossBeforeEquityMethodInvestment	-107641000
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-5198000
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-1010000
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-214529000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-163918000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107641000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.69
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.69
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.15
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.8
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.8
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58071000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58071000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51982000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51982000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38436000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38436000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4908000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3549000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-407000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-209621000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167467000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108048000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	168919000
CY2021	crnx	Transaction Cost On Issuance Of Common Stock TransactionCostOnIssuanceOfCommonStock	12964000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	249542000
CY2021	crnx	Vesting Of Shares Of Common Stock Value Subject To Repurchase VestingOfSharesOfCommonStockValueSubjectToRepurchase	21000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3137000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1021000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17352000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-407000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107641000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	331944000
CY2022	crnx	Transaction Cost On Issuance Of Common Stock TransactionCostOnIssuanceOfCommonStock	7758000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	117242000
CY2022	crnx	Vesting Of Shares Of Common Stock Value Subject To Repurchase VestingOfSharesOfCommonStockValueSubjectToRepurchase	2000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4721000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1618000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28268000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3549000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-163918000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316328000
CY2023	crnx	Transaction Cost On Issuance Of Common Stock TransactionCostOnIssuanceOfCommonStock	22735000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	369080000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20091000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2291000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40937000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4908000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-214529000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	539106000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-214529000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-163918000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107641000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	40937000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	28268000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	17352000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1098000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	983000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	922000
CY2023	crnx	Non Cash Lease Expense NonCashLeaseExpense	1210000
CY2022	crnx	Non Cash Lease Expense NonCashLeaseExpense	406000
CY2021	crnx	Non Cash Lease Expense NonCashLeaseExpense	340000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6271000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-34000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-422000
CY2023	crnx	Noncash License Revenues NoncashLicenseRevenues	2000000
CY2022	crnx	Noncash License Revenues NoncashLicenseRevenues	0
CY2021	crnx	Noncash License Revenues NoncashLicenseRevenues	1078000
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-5198000
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-1010000
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-6000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	crnx	Change In Valuation Of Derivative Assets ChangeInValuationOfDerivativeAssets	0
CY2022	crnx	Change In Valuation Of Derivative Assets ChangeInValuationOfDerivativeAssets	600000
CY2021	crnx	Change In Valuation Of Derivative Assets ChangeInValuationOfDerivativeAssets	0
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4523000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-215000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4361000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14648000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10994000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6293000
CY2023	us-gaap	Increase Decrease In Commodity Contract Assets And Liabilities IncreaseDecreaseInCommodityContractAssetsAndLiabilities	1535000
CY2022	us-gaap	Increase Decrease In Commodity Contract Assets And Liabilities IncreaseDecreaseInCommodityContractAssetsAndLiabilities	-8341000
CY2021	us-gaap	Increase Decrease In Commodity Contract Assets And Liabilities IncreaseDecreaseInCommodityContractAssetsAndLiabilities	0
CY2023	crnx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-546000
CY2022	crnx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-938000
CY2021	crnx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-836000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-166307000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115205000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88588000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	527857000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	329817000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	125404000
CY2023	crnx	Purchase Of Stock Investment PurchaseOfStockInvestment	5000000
CY2022	crnx	Purchase Of Stock Investment PurchaseOfStockInvestment	0
CY2021	crnx	Purchase Of Stock Investment PurchaseOfStockInvestment	0
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	337132000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	157493000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	69357000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4688000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1656000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	436000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200413000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-173980000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56483000
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	22735000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7758000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12964000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	369019000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117242000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	249542000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19925000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4721000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3137000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	388944000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	121963000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	252679000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22224000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-167222000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	107608000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33973000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201195000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93587000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56197000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33973000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201195000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54897000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32672000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200695000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1300000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1301000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	500000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56197000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33973000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201195000
CY2023	crnx	Private Company Shares Received Under Licensing Arrangements PrivateCompanySharesReceivedUnderLicensingArrangements	2000000
CY2022	crnx	Private Company Shares Received Under Licensing Arrangements PrivateCompanySharesReceivedUnderLicensingArrangements	0
CY2021	crnx	Private Company Shares Received Under Licensing Arrangements PrivateCompanySharesReceivedUnderLicensingArrangements	1010000
CY2023	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	0
CY2022	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	0
CY2021	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	68000
CY2023	crnx	Exercise Of Derivative Asset For Investment In Radionetics Common Stock ExerciseOfDerivativeAssetForInvestmentInRadioneticsCommonStock	668000
CY2022	crnx	Exercise Of Derivative Asset For Investment In Radionetics Common Stock ExerciseOfDerivativeAssetForInvestmentInRadioneticsCommonStock	0
CY2021	crnx	Exercise Of Derivative Asset For Investment In Radionetics Common Stock ExerciseOfDerivativeAssetForInvestmentInRadioneticsCommonStock	0
CY2023	crnx	Purchase Of Shares Pursuant To Employee Stock Purchase Plan PurchaseOfSharesPursuantToEmployeeStockPurchasePlan	2291000
CY2022	crnx	Purchase Of Shares Pursuant To Employee Stock Purchase Plan PurchaseOfSharesPursuantToEmployeeStockPurchasePlan	1618000
CY2021	crnx	Purchase Of Shares Pursuant To Employee Stock Purchase Plan PurchaseOfSharesPursuantToEmployeeStockPurchasePlan	1021000
CY2023	crnx	Options Exercise Receivable OptionsExerciseReceivable	166000
CY2022	crnx	Options Exercise Receivable OptionsExerciseReceivable	0
CY2021	crnx	Options Exercise Receivable OptionsExerciseReceivable	0
CY2023	crnx	Common Stock Issued Receivable CommonStockIssuedReceivable	87000
CY2022	crnx	Common Stock Issued Receivable CommonStockIssuedReceivable	0
CY2021	crnx	Common Stock Issued Receivable CommonStockIssuedReceivable	0
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	26000
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	872000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	130000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	46273000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2023	crnx	Lease Incentive Obtained In Exchange For Lease Obligation LeaseIncentiveObtainedInExchangeForLeaseObligation	2925000
CY2022	crnx	Lease Incentive Obtained In Exchange For Lease Obligation LeaseIncentiveObtainedInExchangeForLeaseObligation	0
CY2021	crnx	Lease Incentive Obtained In Exchange For Lease Obligation LeaseIncentiveObtainedInExchangeForLeaseObligation	0
CY2023	crnx	Change In Unvested Stock Liability ChangeInUnvestedStockLiability	0
CY2022	crnx	Change In Unvested Stock Liability ChangeInUnvestedStockLiability	2000
CY2021	crnx	Change In Unvested Stock Liability ChangeInUnvestedStockLiability	21000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-653700000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	558600000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to accrual of research and development expenses, valuation of stock-based awards, fair values of financial instruments, revenue recognition, and the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company’s operating lease right-of-use assets. Estimates are based on historical experiences or on forecasts, including information received from third parties and various other factors that the Company believes are reasonable under the circumstances. Estimates are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">periodically </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates</span>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13743000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10329000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6762000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	502681000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1275000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	298000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	503658000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	305684000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3943000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	301753000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	414031000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	414406000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	246276000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	243542000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	88650000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	89252000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	59408000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	58211000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	502681000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	503658000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	305684000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	301753000
CY2023Q4	crnx	Available For Sale Investment Securities Less Than12 Months Fair Market Value AvailableForSaleInvestmentSecuritiesLessThan12MonthsFairMarketValue	22409000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	15000
CY2023Q4	crnx	Available For Sale Investment Securities More Than12 Months Fair Value AvailableForSaleInvestmentSecuritiesMoreThan12MonthsFairValue	51683000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	283000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	74092000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	298000
CY2022Q4	crnx	Available For Sale Investment Securities Less Than12 Months Fair Market Value AvailableForSaleInvestmentSecuritiesLessThan12MonthsFairMarketValue	196489000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	2151000
CY2022Q4	crnx	Available For Sale Investment Securities More Than12 Months Fair Value AvailableForSaleInvestmentSecuritiesMoreThan12MonthsFairValue	82147000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1792000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	278636000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	3943000
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0
CY2022	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	-86000
CY2021	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	2000
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	3100000
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	1400000
CY2022	crnx	Change In Valuation Of Derivative Asset ChangeInValuationOfDerivativeAsset	600000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2023Q4	crnx	Prepaid Clinical Costs PrepaidClinicalCosts	2574000
CY2022Q4	crnx	Prepaid Clinical Costs PrepaidClinicalCosts	2567000
CY2023Q4	crnx	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	1238000
CY2022Q4	crnx	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	2293000
CY2023Q4	crnx	Foreign Tax Incentive Receivable Current ForeignTaxIncentiveReceivableCurrent	747000
CY2022Q4	crnx	Foreign Tax Incentive Receivable Current ForeignTaxIncentiveReceivableCurrent	937000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	857000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	939000
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	3051000
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1353000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	90000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	135000
CY2023Q4	crnx	Landlord Improvements Receivable LandlordImprovementsReceivable	5210000
CY2022Q4	crnx	Landlord Improvements Receivable LandlordImprovementsReceivable	605000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	253000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1578000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1930000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15598000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10759000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15949000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7584000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5068000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4084000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10881000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3500000
CY2023	us-gaap	Depreciation Depreciation	1100000
CY2022	us-gaap	Depreciation Depreciation	1000000
CY2021	us-gaap	Depreciation Depreciation	900000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6548000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6883000
CY2023Q4	crnx	Accrued Clinical Costs AccruedClinicalCosts	5527000
CY2022Q4	crnx	Accrued Clinical Costs AccruedClinicalCosts	1921000
CY2023Q4	crnx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2312000
CY2022Q4	crnx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	4043000
CY2023Q4	crnx	Accrued Outside Services And Professional Fees AccruedOutsideServicesAndProfessionalFees	1726000
CY2022Q4	crnx	Accrued Outside Services And Professional Fees AccruedOutsideServicesAndProfessionalFees	1810000
CY2023Q4	crnx	Accrued Landlord Improvements2 AccruedLandlordImprovements2	3816000
CY2022Q4	crnx	Accrued Landlord Improvements2 AccruedLandlordImprovements2	359000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3267000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	335000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23196000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	15351000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4491000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7468000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6795000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6999000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7209000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	50975000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	83937000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32209000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	51728000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4173000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47555000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	3300000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2023	crnx	Upfront Payment As License Revenue UpfrontPaymentAsLicenseRevenue	1500000
CY2022	crnx	Upfront Payment As License Revenue UpfrontPaymentAsLicenseRevenue	4700000
CY2023	crnx	Upfront Payment Recognized As Revenues UpfrontPaymentRecognizedAsRevenues	13000000
CY2023	crnx	Summary Of Primary Inputs Used In Valuing The64 Stake In Radionetics And The Radionetics Warrant SummaryOfPrimaryInputsUsedInValuingThe64StakeInRadioneticsAndTheRadioneticsWarrant	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary inputs used in valuing the Radionetics common stock and the Radionetics Warrant, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.191%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:18.404%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:18.404%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Derivative Asset</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 15, 2021 and December 31, 2021</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116.6</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111.4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketability discount</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32344371
CY2023Q3	crnx	Additional Sales Milestones AdditionalSalesMilestones	15000000
CY2023Q4	crnx	Due From Radionetics Current DueFromRadioneticsCurrent	100000
CY2022Q4	crnx	Due From Radionetics Current DueFromRadioneticsCurrent	100000
CY2023	crnx	Reimbursement Earned ReimbursementEarned	100000
CY2022	crnx	Reimbursement Earned ReimbursementEarned	400000
CY2021	crnx	Reimbursement Earned ReimbursementEarned	600000
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150000000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9757329
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.79
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4824597
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.67
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1282603
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	15.66
CY2023	crnx	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndExpired	672199
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.56
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12627124
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.96
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	209884000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12627124
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	18.96
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	209884000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5255484
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.36
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	95731000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	16200000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5900000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5100000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	37000000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	23000000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	16300000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	22210000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40937000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28268000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17352000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	311300000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	228600000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1700000
CY2023Q4	crnx	Federal Loss Carryforwards FederalLossCarryforwards	305000000
CY2023	us-gaap	Tax Credit Carryforward Limitations On Use TaxCreditCarryforwardLimitationsOnUse	These ownership changes may limit the amount of NOL and credit carryforwards that can be utilized to offset future taxable income and income tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. During 2020, the Company completed a study to assess whether an ownership change within the meaning of Section 382 had occurred for the time period prior to July 15, 2020.
CY2023Q4	crnx	Cumulative Change In Ownership Percentage CumulativeChangeInOwnershipPercentage	0.50
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	81828000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	69044000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	43509000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	22123000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	37663000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12207000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8168000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	10889000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	648000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5350000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4208000
CY2023Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3230000
CY2022Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	0
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	194676000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	126401000
CY2023Q4	crnx	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	9799000
CY2022Q4	crnx	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	313000
CY2023Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	0
CY2022Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	140000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9799000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	453000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	184877000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	125948000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-214027000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-163175000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-107723000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-502000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-743000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	82000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-214529000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-163918000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107641000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-45051000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34423000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-22605000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-797000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-128000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7083000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	59951000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	39733000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	34495000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	18179000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	10918000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	7117000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1241000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	781000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1196000
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	35000
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	266000
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	27000
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	44000
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	3243000
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	-8000
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	2691000
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	65000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1446000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1095000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4110000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1553000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1092000
CY2023	crnx	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	188000
CY2022	crnx	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	837000
CY2021	crnx	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-34000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2648000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1720000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	495000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6946000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4110000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1553000
CY2023Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	0
CY2022Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	0
CY2021Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	0
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2023	crnx	Defined Contribution Benefit Plan Effective Date DefinedContributionBenefitPlanEffectiveDate	2016-05-01
CY2023	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	Discretionary matching contributions to the 401(k) Plan are permitted in an amount equal to 50% of the first 6% of the employee’s taxable income up to a maximum of $3,000 per year
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	3000
CY2023	crnx	Accrued Matching Contributions AccruedMatchingContributions	700000
CY2022	crnx	Accrued Matching Contributions AccruedMatchingContributions	500000
CY2021	crnx	Accrued Matching Contributions AccruedMatchingContributions	300000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8333334000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	42
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	350000000

Files In Submission

Name	View Source	Status
0000950170-24-022108-index-headers.html	Edgar Link	pending
0000950170-24-022108-index.html	Edgar Link	pending
0000950170-24-022108.txt	Edgar Link	pending
0000950170-24-022108-xbrl.zip	Edgar Link	pending
crnx-20231231.htm	Edgar Link	pending
crnx-20231231.xsd	Edgar Link	pending
crnx-ex10_14.htm	Edgar Link	pending
crnx-ex19.htm	Edgar Link	pending
crnx-ex23_1.htm	Edgar Link	pending
crnx-ex31_1.htm	Edgar Link	pending
crnx-ex31_2.htm	Edgar Link	pending
crnx-ex32_1.htm	Edgar Link	pending
crnx-ex32_2.htm	Edgar Link	pending
crnx-ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img64906898_0.jpg	Edgar Link	pending
img64906898_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
crnx-20231231_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRNX
Crinetics Pharmaceuticals, Inc. Stock $crnx

2024 Q1 Form 10-K Financial Statement

#000095017024022108 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRNX Crinetics Pharmaceuticals, Inc. Stock $crnx

2024 Q1 Form 10-K Financial Statement

#000095017024022108 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRNX
Crinetics Pharmaceuticals, Inc. Stock $crnx